Researcher.Life Logo

Melanoma Research : Impact Factor & More

eISSN: 1473-5636pISSN: 0960-8931

Aims and Scope of Melanoma Research

Melanoma Research (print: ISSN 0960-8931, online: ISSN 1473-5636) is a peer-reviewed medical journal published by Lippincott Williams & Wilkins since 1991. The journal publishes current findings on melanoma. Articles include both experimental and clinical research in a broad range of related subjects, including genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, and immunology, and advances in clinical oncology influencing the prevention, diagnosis, and treatment of melanoma. Melanoma Research is published bimonthly. The current editor-in-chief is F.J. Lejeune. Less

Key Metrics

CiteScore
6.7
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.88
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Melanoma Research

Melanoma Research Journal Specifications

Overview
Publisher LIPPINCOTT WILLIAMS & WILKINS
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1991
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Melanoma Research ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Melanoma Research

E26 transformation-specific translocation variant 4 participates in melanoma progression and immune evasion by mediating the CD47molecule/signal regulatory protein α pathway.
  • 27 Apr 2026
  • Melanoma research
Expression and prognostic value of cyclase-associated proteins in cutaneous melanoma.
  • 21 Apr 2026
  • Melanoma research
Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.
  • 3 Apr 2026
  • Melanoma research
Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
  • 1 Apr 2026
  • Melanoma research
Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.
  • 1 Apr 2026
  • Melanoma research
Immune-related cholecystitis following combination therapy with nivolumab and ipilimumab in a patient with metastatic melanoma: a case report and literature review.
  • 26 Mar 2026
  • Melanoma research
E26 transformation-specific translocation variant 4 participates in melanoma progression and immune evasion by mediating the CD47molecule/signal regulatory protein α pathway.
  • 27 Apr 2026
  • Melanoma research
Expression and prognostic value of cyclase-associated proteins in cutaneous melanoma.
  • 21 Apr 2026
  • Melanoma research
Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.
  • 3 Apr 2026
  • Melanoma research
Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
  • 1 Apr 2026
  • Melanoma research
Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.
  • 1 Apr 2026
  • Melanoma research
Immune-related cholecystitis following combination therapy with nivolumab and ipilimumab in a patient with metastatic melanoma: a case report and literature review.
  • 26 Mar 2026
  • Melanoma research

FAQs on Melanoma Research